VOOPOO
22.12.2021 11:17:05 CET | Business Wire | Press release
On December 15, 2021, Ecigclick, the well-known vape review site in the UK, announced the results of Ecigclick Vape Awards 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211219005114/en/
VOOPOO products won five awards including the Best Vape Brand 2021, becoming the benchmark brand winning the Best Vape Brand award for two consecutive years.
This outstanding annual achievement in awards, which covers different categories such as Mod, Pod Mod, Pod, Tank, once again verifies VOOPOO's excellent global brand influence. Its diversified product lineup has been recognized by the market and is well received by vapers worldwide.
The Ecigclick Vape Awards attracted more than 200 mainstream brands competing in various categories. More than 100,000 global vapers of mainstream communities from North America, the United Kingdom, and the European Union participated in the email voting.
This year, VOOPOO's four products (ARGUS, DRAG Nano 2, DRAG 3, TPP-X POD TANK) won the Best Vape Kit For Beginners, the Best POD, the Best MOD, and the Best Sub Ohm Tank respectively, thanks to VOOPOO's consumer-based insight and diversified product strategy.
It is with the changes in the market environment and technological innovation that vapers are getting more demanding. Scenario-based, lightweight and diversified products are becoming more and more popular in the market.
In view of this, VOOPOO invested in new product series based on vaper value, and launched a product lineup integrating DRAG, VINCI, ARGUS, and V series to provide vapers with more suitable product solutions and to continue to enhance vaper experience.
Every vaper can find his favorite way to experience, no matter what he likes — Mod, Pod Mod or Pod. VOOPOO respects the vapers' own choice and is pleased to diversify its offering.
VOOPOO will continue to develop its product ecosystem, allowing its DRAG, VINCI, ARGUS, and V series to integrate with each other, so that consumers can enjoy a safe, reliable, and diverse product ecosystem that can meet diversified needs.
About VOOPOO
Founded in 2017, VOOPOO has rapidly grown through DRAG products within a short period of time and is well recognized by vapers from around the world. VOOPOO is a high-tech enterprise integrating R&D, design, production and brand operations. It has four flagship product series: DRAG, VINCI, ARGUS and V Series. Its business covers more than 70 countries and regions in North America, Europe and Asia. For more information, please visit our website and follow our IG , Facebook and TikTok .
About Ecigclick
Ecigclick is one of the vape sites with the widest coverage and most active vapers in the world. Ecigclick Vape Awards, as its annual voting event, has been successfully held for 9 years. Its forward-looking ranking is well recognized and has a deep influence in the industry.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211219005114/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom